Want a robust quality drug pipeline? – Pay super premium!: Alexion to acquire Synageva in an $8.4bn deal

Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn   Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…

Get a $66bn Smile: Actavis to buy the Botox-maker Allergan

Actavis plc.; market cap (as of 21/11/2014): $70.5bn Allergan Inc.; market cap (as of 21/11/2014): $63.3bn Introduction The growing emphasis we put on health and quality of life, and the scientific advancements which are making this possible, are putting the pharmaceutical and medical industries in the spotlight. The recent surge Read more…